BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity

Anti-Cancer Drugs

Volumn 22, Issue 10, 2011, Pages 995-1001

  Morales, Andressa G ^a   Brassesco, María S ^b   Pezuk, Julia A ^a   Oliveira, Jaqueline C ^a   Montaldi, Ana P ^a   Sakamoto Hojo, Elza T ^b   Scrideli, Carlos A ^b   Tone, Luiz G ^b  

^a Department of Genetics ^*  (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

BI 2536; clonogenicity; mitotic arrest; mitotic catastrophy; necrosis; osteosarcoma

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CASPASE 3; POLO LIKE KINASE 1;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CLONOGENESIS; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOSIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CASPASE 3; CELL CYCLE PROTEINS; CELL DEATH; CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MITOSIS; OSTEOSARCOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES;

EID: 80053629548     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834a16d4     Document Type: Article

References (19)

1. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and Genetics of Tumours of Soft Tissue and Bone. World Health Organization Classification of Tumours. 2002; Lyon: IARC Press; 2002.
2. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009; 152:239-262.
3. Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, et al. Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. Cancer Lett 2010; 293:220-229.
4. Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, et al. Inhibition of pololike kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 2011; 22:444-453.
5. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-322. (Pubitemid 46241881)
6. Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1:2315-2319.
7. Lee Y, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. The J Biol Chem 1999; 274:19792-19798.
8. Schmit TL, Zhong W, Setaluri V, Spiegelman Versus, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129:2843-2853.
9. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005; 24:260-266. (Pubitemid 40188606)
10. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-660.
11. Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 2002; 277:32282-32293. (Pubitemid 34969045)
12. Fink J, Sanders K, Rippl A, Finkernagel S, Beckers TL, Schmidt M. Cell type dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Mol Cancer Ther 2007; 6:3189-3197.
13. Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, et al. Functional genome screen for therapeutic targets of osteosarcoma. Cancer Sci 2009; 100:2268-2274.
14. Decker S, Winkelmann W, Nies B, Van Valen F. Cytotoxic effect of methotrexate and its solvent on osteosarcoma cells in vitro. J Bone Joint Surg Br 1999; 81:545-551. (Pubitemid 29245916)
15. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci U S A 2002; 99:8672-8676. (Pubitemid 34693618)
16. Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr Biol 2007; 17:R280-R283. (Pubitemid 46566537)
17. Portugal J, Bataller M, Mansilla S. Cell death pathways in response to antitumor therapy. Tumori 2009; 95:409-421.
18. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15:1153-1162. (Pubitemid 351850968)
19. Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114:659-662.